Companies in the News

4.2.2019

Phase 1 results and new translational data supporting the development of BTRX-335140 for neurobehavioral disorders presented at the Kappa Therapeutics 2019 Conference

San Francisco – April 1, 2019 – BlackThorn Therapeutics, a neurobehavioral health company leveraging its proprietary computational psychiatr...

Please reload